14.74
0.10 (0.68%)
| Previous Close | 14.64 |
| Open | 14.50 |
| Volume | 13,054 |
| Avg. Volume (3M) | 81,922 |
| Market Cap | 306,650,304 |
| Price / Sales | 1.42 |
| Price / Book | 0.660 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -41.07% |
| Operating Margin (TTM) | -39.88% |
| Diluted EPS (TTM) | -4.40 |
| Quarterly Revenue Growth (YOY) | -25.70% |
| Total Debt/Equity (MRQ) | 2.18% |
| Current Ratio (MRQ) | 3.53 |
| Operating Cash Flow (TTM) | -30.88 M |
| Levered Free Cash Flow (TTM) | 9.06 M |
| Return on Assets (TTM) | -5.06% |
| Return on Equity (TTM) | -17.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bullish | Mixed |
| Drug Manufacturers - General (Global) | Bullish | Mixed | |
| Stock | Amarin Corporation plc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.70 |
|
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| % Held by Insiders | 1.88% |
| % Held by Institutions | 17.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sarissa Capital Management Lp | 31 Dec 2025 | 1,673,395 |
| Kynam Capital Management, Lp | 31 Dec 2025 | 389,273 |
| Eversept Partners, Lp | 31 Dec 2025 | 172,188 |
| Waterfront Wealth Inc. | 31 Dec 2025 | 142,540 |
| Scp Investment, Lp | 31 Dec 2025 | 100,000 |
| Lcm Capital Management Inc | 31 Dec 2025 | 42,262 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FISHMAN PETER L. | - | 14.64 | -62 | -908 |
| Aggregate Net Quantity | -62 | |||
| Aggregate Net Value ($) | -908 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 14.64 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FISHMAN PETER L. | Officer | 01 Apr 2026 | Disposed (-) | 62 | 14.64 | 908 |
| FISHMAN PETER L. | Officer | 01 Apr 2026 | Option execute | 125 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |